Advanced sleep phase syndrome gen in humans

• US 20040146873A1
• Filed: 06/24/2003
• Published: 07/29/2004
• Est. Priority Date: 01/11/2002
• Status: Abandoned Application

• Current Assignee: University of Utah (State of Utah)
• Original Assignee: University of Utah (State of Utah)
• Inventors: Virshup, David, Jones, Christopher, Ptacek, Louis, Fu, Ying-Hui
• Application Number:
  US10/451,689
• Publication Number:
  US 20040146873A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/485 involving kinase
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 2800/2864 Sleep disorders
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes
• CPC Class Codes: G01N 33/6875 Nucleoproteins
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The present invention includes the disclosure of the hPER2 gene and a mutant of the hPER2 gene that participates in the human circadian biological clock. The product of the mutant hPER2 gene found in some familial advanced sleep phase syndrome patients is hypophosphorylated by casein kinase epsilon due to the serine-to-glycine mutation caused by the point mutation of the genomic sequence. Specifically, this serine-to-glycine mutation affects the casein kinase epsilon binding region of the hPER2 protein, thus blocking the phosphorylation cascade ordinarily caused by the binding of casein kinase epsilon to hPER2.

Claims

1. A method of diagnosing Familial Advanced Sleep Phase Syndrome in a human subject comprising:

screening for an alteration in a germline copy of the hPer2 gene of the human subject, wherein the detection of an alteration in the germline copy of the hPer2 gene of the human subject indicates a positive diagnosis of Familial Advanced Sleep Phase Syndrome in the human subject.

2. The method of claim 1, wherein the step of screening for an alteration in a germline copy of the hPer2 gene of the human subject comprises comparing the sequence of the germline copy of the hPer2 gene from the subject with a germline sequence of a wild-type hPer2 gene.

3. The method of claim 1, wherein the step of screening for an alteration in a germline copy of the hPer2 gene of the human subject comprises sequencing a germline copy of the hPer2 gene from the human subject and comparing the sequence of the germline copy of the hPer2 gene to a sequence with a known alteration in the hPer2 gene, wherein the sequence of the hPer2 gene that is substantially identical to the sequence with a known alteration in the hPer2 gene indicates an alteration in the germline copy of the hPer2 gene from the human subject.

4. The method of claim 3, wherein the sequence with a known alteration in the hPer2 gene is SEQ ID NO. 2.

5. The method of claim 2, further comprising the initial steps of obtaining a tissue sample from the human subject, isolating a germline copy of the hPer2 gene of the human subject from the tissue sample, and sequencing the isolated germline copy of the hPer2 gene prior to comparing the sequence of the germline copy of the hPer2 gene from the subject with a germline sequence of a wild-type hPer2 gene.

6. A method of diagnosing Familial Advanced Sleep Phase Syndrome in a human subject comprising:

screening for an alteration in the hPer2 polypeptide of the human subject, wherein the detection of an alteration in hPer2 polypeptide of the human subject indicates a positive diagnosis of Familial Advanced Sleep Phase Syndrome in the human subject.

7. The method of claim 6, wherein the step of screening for an alteration in the hPer2 polypeptide of the human subject comprises comparing the sequence of a hPer2 polypeptide from the subject with a wild-type hPer2 polypeptide.

8. The method of claim 6, wherein the step of screening for an alteration in the hPer2 polypeptide of the human subject comprises sequencing a hPer2 polypeptide from the human subject and comparing the sequence of the hPer2 polypeptide to a sequence with a known alteration in the hPer2 polypeptide, wherein the sequence of the hPer2 polypeptide that is identical to the sequence with a known alteration in the hPer2 polypeptide indicates an alteration in the hPer2 polypeptide from the human subject.

9. The method of claim 8, wherein the sequence with a known alteration in the hPer2 gene is SEQ ID NO. 3.

10. The method of claim 6, further comprising the initial steps of obtaining a tissue sample from the human subject, isolating a hPer2 polypeptide of the human subject from the tissue sample, and sequencing the isolated hPer2 polypeptide prior to comparing the sequence of the hPer2 polypeptide from the subject with a wild-type hPer2 polypeptide.

11. A method of diagnosing Familial Advanced Sleep Phase Syndrome in a human subject comprising:

screening for hypophosphorylation of hPer2 polypeptides of the human subject, wherein the detection of hypophosphorylation of hPer2 polypeptides of the human subject indicates a positive diagnosis of Familial Advanced Sleep Phase Syndrome in the human subject.

12. The method of claim 11, wherein the step of screening for hypophosphorylation of hPer2 polypeptides of the human subject comprises comparing the amount of phosphorylation of hPer2 polypeptides from the subject with the amount of phosphorylation of wild-type hPer2 polypeptides.

13. The method of claim 11, further comprising the initial step of obtaining hPer2 polypeptides from fibroblast cells taken from the human subject.

14. A method of screening for inhibitors of casein kinase epsilon comprising the steps of:

contacting a potential inhibitor of casein kinase I epsilon with casein kinase I epsilon in the presence of hPER2 and phosphates;

measuring the level of phosphorylation of the hPER2, wherein a level of phosphorylation observed with the potential inhibitor lower than a level of phosphorylation observed when casein kinase I epsilon is contacted with hPER2 and phosphates without the potential inhibitor signals an inhibitor of casein kinase I epsilon.

15. The method of claim 14, wherein the step of measuring the level of phosphorylation of the hPER2 comprises electrophoresis, wherein an electrophoretic mobility shift of the hPER2 resulting from the method from that observed with hPER2 not subjected to the method denotes phosphorylation.

16. The method of claim 15, further comprising the step of treating the hPER2 with phosphatase to confirm that the mobility shift is due to phosphorylation.

17. A method of screening for compounds which upregulate the phosphorylation of hPER2 by casein kinase I epsilon comprising the steps of:

contacting a potential upregulating compound with casein kinase I epsilon in the presence of hPER2 and phosphates;

measuring the level of phosphorylation of the hPER2, wherein a level of phosphorylation observed with the potential upregulating compound higher than a level of phosphorylation observed when casein kinase I epsilon is contacted with hPER2 and phosphates without the potential upregulating compound signals an upregulating compound for casein kinase I epsilon.

18. The method of claim 17, wherein the step of measuring the level of phosphorylation of the hPER2 comprises electrophoresis, wherein an electrophoretic mobility shift of the hPER2 resulting from the method from that observed with hPER2 not subjected to the method denotes phosphorylation.

19. The method of claim 17, further comprising the step of treating the hPER2 with phosphatase to confirm that the mobility shift is due to phosphorylation.

20. An isolated and purified nucleic acid molecule comprising a nucleotide sequence which encodes an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:

1.

21. An isolated and purified nucleic acid molecule comprising a nucleotide sequence which encodes an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:

1.

22. An isolated and purified nucleic acid molecule comprising a nucleotide sequence which encodes an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:

1.

23. An isolated and purified nucleic acid molecule comprising a nucleotide sequence which encodes the amino acid sequence of SEQ ID NO:

1.

24. An isolated nucleic acid molecule having the sequence found in SEQ. ID NO:

2.

25. The nucleic acid molecule of claim 24, wherein the nucleic acid molecule is subcloned into a plasmid.

26. The nucleic acid molecule of claim 24, wherein the nucleic acid molecule is subcloned into a prokaryotic or eukaryotic expression vector.

27. The nucleic acid molecule of claim 24, wherein the nucleic acid molecule is operably linked to a heterologous promoter.

28. The nucleic acid molecule of claim 24, wherein the nucleic acid molecule is stably or transiently incorporated into a prokaryotic or eukaryotic host cell.

29. A method for treating advanced sleep phase syndrome of aging in a human subject comprising administering AzaC to the human subject.

30. A method for treating advanced sleep phase syndrome of aging in a human subject comprising administering a histone deacetylase inhibitor to the subject.

31. A method of screening for inhibitors of casein kinase I delta comprising the steps of:

contacting a potential inhibitor of casein kinase I delta with casein kinase I delta in the presence of hPER2 and phosphates;

measuring the level of phosphorylation of the hPER2, wherein a level of phosphorylation observed with the potential inhibitor lower than a level of phosphorylation observed when casein kinase delta is contacted with hPER2 and phosphates without the potential inhibitor signals an inhibitor of casein kinase I delta.

32. The method of claim 31, wherein the step of measuring the level of phosphorylation of the hPER2 comprises electrophoresis, wherein an electrophoretic mobility shift of the hPER2 resulting from the method from that observed with hPER2 not subjected to the method denotes phosphorylation.

33. The method of claim 32, further comprising the step of treating the hPER2 with phosphatase to confirm that the mobility shift is due to phosphorylation.

34. A method of screening for compounds which upregulate the phosphorylation of hPER2 by casein kinase I delta comprising the steps of:

contacting a potential upregulating compound with casein kinase I delta in the presence of hPER2 and phosphates;

measuring the level of phosphorylation of the hPER2, wherein a level of phosphorylation observed with the potential upregulating compound higher than a level of phosphorylation observed when casein kinase I delta is contacted with hPER2 and phosphates without the potential upregulating compound signals an upregulating compound for casein kinase I delta.

35. The method of claim 34, wherein the step of measuring the level of phosphorylation of the hPER2 comprises electrophoresis, wherein an electrophoretic mobility shift of the hPER2 resulting from the method from that observed with hPER2 not subjected to the method denotes phosphorylation.

36. The method of claim 35, further comprising the step of treating the hPER2 with phosphatase to confirm that the mobility shift is due to phosphorylation.

37. A method of screening for compounds that inhibit the phosphorylation of hPER2 comprising the steps of:

contacting a potential inhibitor of the phosphorylation of hPER2 with hPER2 in the presence of a kinase and phosphates;

measuring the level of phosphorylation of the hPER2, wherein a level of phosphorylation observed with the potential inhibitor of the phosphorylation of hPER2 lower than a level of phosphorylation observed when hPER2 is contacted with a kinase and phosphates without the potential inhibitor of the phosphorylation of hPER2 signals an inhibitor of the phosphorylation of hPER2.

38. The method of claim 37, wherein the kinase is casein kinase I epsilon.

39. The method of claim 37, wherein the kinase is casein kinase delta.

40. The method of claim 37, wherein the step of measuring the level of phosphorylation of the hPER2 comprises electrophoresis, wherein an electrophoretic mobility shift of the hPER2 resulting from the method from that observed with hPER2 not subjected to the method denotes phosphorylation.

41. The method of claim 40, further comprising the step of treating the hPER2 with phosphatase to confirm that the mobility shift is due to phosphorylation.

43. The method of claim 37, wherein the kinase is casein kinase I epsilon.

44. The method of claim 37, wherein the kinase is casein kinase delta.

42. A method of screening for compounds that upregulate the phosphorylation of hPER2 comprising the steps of:

contacting a potential upregulating compound of the phosphorylation of hPER2 with hPER2 in the presence of a kinase and phosphates;

measuring the level of phosphorylation of the hPER2, wherein a level of phosphorylation observed with the potential upregulating compound of the phosphorylation of hPER2 higher than a level of phosphorylation observed when hPER2 is contacted with a kinase and phosphates without the potential upregulating compound of the phosphorylation of hPER2 signals an upregulating compound for the phosphorylation of hPER2.

45. The method of claim 42, wherein the step of measuring the level of phosphorylation of the hPER2 comprises electrophoresis, wherein an electrophoretic mobility shift of the hPER2 resulting from the method from that observed with hPER2 not subjected to the method denotes phosphorylation.

46. The method of claim 45, further comprising the step of treating the hPER2 with phosphatase to confirm that the mobility shift is due to phosphorylation.